The scrutiny centers on whether executives at the NASDAQ-listed firm suppressed material information or provided false guidance concerning new patient starts, a critical metric for the company's valuation. On January 8, 2026, Beta Bionics disclosed preliminary fourth-quarter results showing at least 5,581 new patient starts, a 36% year-over-year increase. While the company maintained growth, the figures fell short of analyst expectations and represented a significant cooling from the 68% growth rate reported just one quarter earlier.

Investors who incurred losses following these disclosures are now being evaluated for potential securities law claims. Johnson Fistel, which previously recovered over $90 million for clients in 2024, is seeking to determine if public statements made by Beta Bionics officials created a distorted view of the company’s actual market momentum. Shareholders interested in the investigation have been invited to contact the firm to review their legal rights.